Monitoring of hepatitis B virus surface antigen escape mutations and concomitantly nucleos(t)ide analog resistance mutations in Turkish patients with chronic hepatitis B
| Autor: | Omer Senturk, Sıla Akhan, Sadettin Hülagü, Murat Sayan, Mustafa Cekmen |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Microbiology (medical) HBsAg Hepatitis B virus Adolescent Genes Viral Turkey Gene Products pol medicine.disease_cause Young Adult Hepatitis B Chronic Gene Frequency Telbivudine Drug Resistance Viral medicine Humans Child Aged Hepatitis B Surface Antigens Base Sequence Nucleotides business.industry Infant Lamivudine Nucleosides General Medicine Entecavir Middle Aged Hepatitis B medicine.disease Virology Infectious Diseases HBeAg Nucleos(t)ide analogs Child Preschool Drug resistance DNA Viral Mutation HBsAg escape mutation Female Viral hepatitis business medicine.drug |
| Zdroj: | International Journal of Infectious Diseases. 14:e136-e141 |
| ISSN: | 1201-9712 |
| DOI: | 10.1016/j.ijid.2009.11.039 |
| Popis: | Summary Background The hepatitis B virus (HBV) polymerase gene completely overlaps with the envelope gene. In the present study we aimed to monitor the prevalence and pattern of the typical mutations for hepatitis B surface antigen (HBsAg) escape, and concomitantly nucleos(t)ide analog (NUC) resistance mutations, in Turkish patients undergoing different antiviral therapies and in treatment-naive patients with chronic hepatitis B (CHB). Methods The investigation was undertaken between March 2007 and August 2009 and involved a total of 142 patients under NUC therapy (88 males; mean age 42 years (range 13–68); hepatitis B e antigen (HBeAg) negativity in 94 patients; HBV DNA median log 4.3 log 10 IU/ml (range 2.0–>6.0); alanine aminotransferase (ALT) median level 76.1 IU/ml (range 12–1082)) and 185 treatment-naive CHB patients (120 males; mean age 39 years (range 1–76 years); HBeAg negativity in 132 patients; HBV DNA median log 3.5 log 10 IU/ml (range 2.0–6.0); ALT median level 60.7 IU/l (range 8–874)). Results The overall prevalence of typical HBsAg escape mutations found in the CHB patients was 8.3% (27/327). In the NUC therapy group the prevalence was 8.5% (12/142), with the following patterns: sY100C+sI110V, sL109I, sP120T, sP127T, sG130R+sG145X, sS132A+sY134N, sY134N+sG145R, sC137G, sD144E, sG145R. In the treatment-naive group the prevalence was 8.1% (15/185), with the following patterns: sL109I, sI110V, sS117INST, sP120T, sP127T, sM133I, sC137L+sG145R, sS143L. However, NUC resistance mutations were found in 7.7% (11/142) of the patients on NUC therapy and 3.8% (7/185) of the treatment-naive group patients. Interestingly, the treatment-naive patients had preexisting drug resistance mutations related to lamivudine (rtL180M+rtM204I), adefovir (rtA181V, rtQ215S, rtI233V), entecavir (intermediate susceptibility with rtL180M+rtM204IHBV variant), telbivudine (rtL180M+rtM204I), and tenofovir (rtA194T). Conclusions The findings of this study show preexisting typical HBsAg escape and NUC resistance mutations are possible. The genetic arrangement of the HBV genome with polymerase and surface genes overlapping has substantial public health and diagnostic implications and relevance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|